The Association of COVID-19 and Patients Diagnosed with Lung Cancer
Main Article Content
Abstract
Objectives: The COVID-19 pandemic’s impact on the healthcare system resulted in decreased rates of screening, diagnosis, and treatment of lung malignancies. Long-term longitudinal studies are needed to analyze resultant stage migration.
Materials and Methods: Retrospective cohort study of patients diagnosed with a primary thoracic malignancy (lung, main bronchus, hilum, and carina) who received first-course therapy at a single institution. Clinical and pathological staging values were compared utilizing 12 and 22-month timeframes before (pre-COVID-19) and after (post-COVID-19) the outbreak of the pandemic.
Results: A total of 1,002 patients with clinical stage 0 to IV and 538 patients with pathological stage 0 to IV were analyzed in the pre-COVID-19 and post-COVID-19 populations. Between the 12-month pre- and post-COVID-19 groups, clinical T4 significantly increased (+9.68%). In the 22-month pre- and post-COVID-19 groups, clinical T2 decreased (-7.15%) and T4 increased (+11.53%), pathological T2 decreased (-8.97%) and T4 increased (+8.89%), clinical N2 increased (+6.26%), pathological N0 decreased (-9.22%) and N2 increased (+8.91%), clinical M0 decreased (-8.47%) and M1 increased (+8.47%), pathologic M0 decreased (-11.23%) and M1 increased (+11.23%), clinical stage II decreased (-4.28%) and IV increased (+7.78%), and pathologic stage II decreased (-8.06%) and stage IV increased (+11.08%).
Conclusions: Following the COVID-19 pandemic, significant decreases in the number and availability of lung cancer screenings emerged. This study found statistically significant stage migration at initial diagnosis, particularly when analyzing lengthened time periods of 22 months post-COVID-19 compared to 12 months. Stage migration following the COVID-19 pandemic appears to become more distinguished over time.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Barsouk A, Saginala K, Aluru JS, Rawla P, Barsouk A. US Cancer Screening Recommendations: Developments and the Impact of COVID-19. Med Sci (Basel). 2022;10(1):16. Published 2022 Mar 1. doi:10.3390/medsci10010016
3. Van Haren RM, Delman AM, Turner KM, et al. Impact of the COVID-19 Pandemic on Lung Cancer Screening Program and Subsequent Lung Cancer. J Am Coll Surg. 2021;232(4):600-605. doi:10.1016/j.jamcollsurg.2020.12.002
4. US Preventive Services Task Force, Krist AH, Davidson KW, et al. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(10):962-970. doi:10.1001/jama.2021.1117
5. Mazzone PJ, Gould MK, Arenberg DA, et al. Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic: CHEST Expert Panel Report. Chest. 2020;158(1):406-415. doi:10.1016/j.chest.2020.04.020
6. Kaufman HW, Chen Z, Niles J, Fesko Y. Changes in the Number of US Patients With Newly Identified Cancer Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic [published correction appears in JAMA Netw Open. 2020 Sep 1;3(9):e2020927. doi: 10.1001/jamanetworkopen.202 0.20927]. JAMA Netw Open. 2020;3(8):e2017267. Published 2020 Aug 3. doi:10.1001/jamanetworkopen.2020.17267
7. Patt D, Gordan L, Diaz M, et al. Impact of COVID-19 on Cancer Care: How the Pandemic Is Delaying Cancer Diagnosis and Treatment for American Seniors. JCO Clin Cancer Inform. 2020; 4:1059-1071. doi:10.1200/CCI.20.00134
8. Mynard N, Saxena A, Mavracick A, et al. Lung Cancer Stage Shift as a Result of COVID-19 Lockdowns in New York City, a Brief Report. Clin Lung Cancer. 2022;23(3):e238-e242. doi:10.1016/j.cllc.2021.08.010
9. Cantini L, Mentrasti G, Russo GL, et al. Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario. ESMO Open. 2022;7(2):100406. doi:10.1016/j.esmoop.2022.100406
10. Minamimoto R, Hotta M, Okafuji T, et al. Change in cancer diagnosis during the COVID-19 pandemic: Trends estimated from FDG-PET/CT. Glob Health Med. 2022;4(2):108-115. doi:10.35772/ghm.2022.01016
11. Terashima T, Tsutsumi A, Iwami E, Kuroda A, Nakajima T, Eguchi K. Delayed visit and treatment of lung cancer during the coronavirus disease 2019 pandemic in Japan: a retrospective study. J Int Med Res. 2022;50(5):3000605221097375. doi:10.1177/03000605221097375
12. Park JY, Lee YJ, Kim T, et al. Collateral effects of the coronavirus disease 2019 pandemic on lung cancer diagnosis in Korea. BMC Cancer. 2020;20 (1):1040. Published 2020 Oct 29. doi:10.1186/s12885-020-07544-3
13. Mangone L, Marinelli F, Bisceglia I, et al. The Influence of COVID-19 on New Lung Cancer Diagnoses, by Stage and Treatment, in Northern Italy. Biology (Basel). 2023;12(3):390. Published 2023 Feb 28. doi:10.3390/biology12030390
14. Mojsak D, Dębczyński M, Kuklińska B, et al. Impact of COVID-19 in Patients with Lung Cancer: A Descriptive Analysis. Int J Environ Res Public Health. 2023;20(2):1583. Published 2023 Jan 15. doi:10.3390/ijerph20021583
15. Priou S, Lamé G, Zalcman G, et al. Influence of the SARS-CoV-2 outbreak on management and prognosis of new lung cancer cases, a retrospective multicenter real-life cohort study. Eur J Cancer. 2022;173:33-40. doi:10.1016/j.ejca.2022.06.018
16. Keogh JAJ, Chhor AD, Begum H, Akhtar-Danesh N, Finley C. Impact of the COVID-19 pandemic on non-small-cell lung cancer pathologic stage and presentation. Can J Surg. 2022;65(4):
E496-E503. Published 2022 Aug 4. doi:10.1503/cjs.016721
17. Zhang Y, Li J, Li ZK, et al. Impact of Coronavirus Disease 2019 on Clinical Characteristics in Patients With Lung Cancer: A Large Single-Centre Retrospective Study. Front Oncol. 2021;11:693002. Published 2021 Aug 16.
doi:10.3389/fonc.2021.693002
18. Kasymjanova G, Rizzolo A, Pepe C, et al. The Impact of COVID-19 on the Diagnosis and Treatment of Lung Cancer over a 2-Year Period at a Canadian Academic Center. Curr Oncol. 2022; 29(11):8677-8685. Published 2022 Nov 14. doi:10.3390/curroncol29110684